PYONG Rehabilitation Group
Bookimedは神経変性疾患治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。神経変性疾患治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。神経変性疾患治療の旅路でお一人になることはありません。
再生医療専門医 – トントーイシン医師は、ベガクリニックにて神経変性疾患に対する最先端治療を専門としています。
Board-certified physiatrist (Diplomate of the Thai Board of Rehabilitation Medicine, 2023). Head of Rehabilitation at King Mongkut Chaokhunthahan Hospital. CEO and Founder of PYONG Rehabilitation Group since 2023.
Clinical focus: neurorehabilitation, geriatric rehabilitation, and chronic pain. Uses robotics and wearable exoskeleton gait training. Performs ultrasound-guided procedures and advanced laser and radiofrequency therapies.
Principal Investigator of a pilot randomized controlled trial on wearable exoskeleton gait training in subacute stroke. Presented to the Royal College of Physiatrists of Thailand in 2023. Instructor at KMITL since 2020.
Completed Rehabilitation Medicine residency at Chulalongkorn University in 2023. Earned an MD in 2017. Runs a public health platform with over 100,000 followers. Hosted PYONG SUMMIT in 2024 with over 200 attendees. Honors include nominee for Quality Person of the Year 2025 and First Prize in the Ananda Mahidol Pin Design in 2016.
Dr. Tara Rak-areekul is a neurologist focused on cognitive neurology. She is a fellow at King Chulalongkorn Memorial Hospital. She completed her neurology residency there and served as Chief of Academic in 2023. She holds an MD from Chulalongkorn University (Second Class Honors) and a Higher Graduate Diploma in Clinical Sciences. She is certified in NIHSS (2022) and the Thai Stroke Society Acute Stroke Treatment Course.
Key achievements include first rank in the National Formative Neurological Exam (2023). She won the Epilepsy Quiz Tournament (2023). She was first runner-up at the Neurology Tournaments at NST Midyear 2023 and the Chula Neuroscience Forum 2022. Her research includes AAIC poster presentations (2024, 2025). Ongoing work covers Alzheimer’s biomarkers (MDS‑OAβ and p‑tau217), the Thai clinical adaptation of HippoCamera, and a chapter on behavioral and psychological symptoms of dementia (BPSD).